Periodic aggregate safety reporting is a regulatory requirement throughout clinical development and the full commercial lifecycle of a medicinal product. Sponsors and Marketing Authorization Holders (MAHs) must submit comprehensive safety data to health authorities at defined intervals to support ongoing evaluation of the product's benefit-risk profile. These requirements—including timelines, frequency, and report formats—vary across global markets.
CareLyft supports organizations with accurate, timely, and high-quality aggregate safety reporting, ensuring submissions are delivered in the appropriate format and aligned with country-specific regulatory expectations. Our experts combine scientific rigor with regulatory insight to deliver consistent, inspection-ready outputs.
As a full-service pharmacovigilance provider, CareLyft continuously monitors evolving regulatory requirements and assesses their impact on reporting processes—ensuring sustained compliance, audit readiness, and operational resilience.